Scholarlink

<p>Non-Hodgkin’s lymphomas constitute a&#xa0;highly heterogeneous group of neoplasms. Their origin lies in the lymphatic cells of our immune system. Despite their biological variance, they can be clinically classified into indolent and aggressive lymphomas. This categorization has prognostic and therapeutic implications. The goal of treatment in aggressive lymphoma is full remission, which usually requires an intensive treatment regimen. In cases of indolent lymphoma, cure is not the therapeutic goal, but rather disease control. Recent developments have led to novel therapeutic options in addition to the classic well-known chemotherapies and anti-CD20 antibodies. The use of a&#xa0;variety of targeted therapies, including cellular therapies such as chimeric antigen receptor (CAR) T&#xa0;cells, has led to significantly improved outcomes.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Non-Hodgkin-Lymphome – ein kurzer Überblick

  • 期刊论文

  • 发表日期：

    2025年3月13日

查看全文
  • S. Pudasaini,
  • M. Dreyling

摘要

Non-Hodgkin’s lymphomas constitute a highly heterogeneous group of neoplasms. Their origin lies in the lymphatic cells of our immune system. Despite their biological variance, they can be clinically classified into indolent and aggressive lymphomas. This categorization has prognostic and therapeutic implications. The goal of treatment in aggressive lymphoma is full remission, which usually requires an intensive treatment regimen. In cases of indolent lymphoma, cure is not the therapeutic goal, but rather disease control. Recent developments have led to novel therapeutic options in addition to the classic well-known chemotherapies and anti-CD20 antibodies. The use of a variety of targeted therapies, including cellular therapies such as chimeric antigen receptor (CAR) T cells, has led to significantly improved outcomes.